An open portfolio of interoperable, industry leading products
The Dotmatics digital science platform provides the first true end-to-end solution for scientific R&D, combining an enterprise data platform with the most widely used applications for data analysis, biologics, flow cytometry, chemicals innovation, and more.
Through 00-12, the FDA rejected approximately 29% of first-time marketing applications of NMEs due to uncertainties related to dose selection and choice of endpoint.
For those that resubmitted, the median delay to approval was a further 435 days. In 2016, a statistical approach received approval from the FDA as a strategy to overcome these problems.
In our upcoming webinar, we will provide practical examples of how to use this approach for your dose-finding study through various endpoints..
Speaker: Brian Fox, Research Statistician, Statsols
Duration: 60 minutes
Nothing showing? Click here to accept marketing cookies
These Stories on Guide to Sample Size
Copyright © Statsols. All Rights Reserved. Do Not Sell or Share My Personal Information | Privacy Policy | License Agreement | Legal Disclaimers
No Comments Yet
Let us know what you think